Introduction to monoclonal antibodies.
作者信息
Mach Jean-Pierre
机构信息
Department of Biochemistry, University of Lausanne, Epalinges, Switzerland.
出版信息
Cancer Immun. 2012;12:11. Epub 2012 May 1.
Abstract
摘要
相似文献
1
Introduction to monoclonal antibodies.单克隆抗体简介。
Cancer Immun. 2012;12:11. Epub 2012 May 1.
2
Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy.放射性标记的单克隆抗肿瘤抗体在诊断和治疗中的应用。
J Nucl Med. 1985 May;26(5):538-45.
3
Monoclonal antibodies in nuclear medicine.核医学中的单克隆抗体。
J Nucl Med. 1985 May;26(5):531-7.
4
Radiolabeling of monoclonal antibodies.单克隆抗体的放射性标记
Hybridoma. 1986 Jul;5 Suppl 1:S39-42.
5
Radioimmunodetection and radioimmunotherapy.
Cancer Invest. 1984;2(5):363-81. doi: 10.3109/07357908409040313.
6
[Radiolabeled monoclonal antibodies as anti-tumor missiles, their diagnostic success and therapeutic potential].[放射性标记单克隆抗体作为抗肿瘤导弹，其诊断成效与治疗潜力]
Bull Acad Natl Med. 1992 Jun;176(6):879-89.
7
Radiolabeled monoclonal antibodies: radiochemical pharmacokinetic and clinical challenges.放射性标记单克隆抗体：放射化学药代动力学及临床挑战
J Nucl Med. 1985 May;26(5):546-8.
8
High efficiency iodination of monoclonal antibodies for radiotherapy.用于放射治疗的单克隆抗体的高效碘化
J Nucl Med. 1987 Jun;28(6):1034-6.
9
Monoclonal antibodies: prospects for specific immunotherapy for gliomas.单克隆抗体：胶质瘤特异性免疫治疗的前景
Am J Clin Oncol. 1987 Aug;10(4):278-80.
10
Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates.利用金属螯合物对单克隆抗体进行放射性标记的新方法。
Int J Rad Appl Instrum B. 1991;18(4):369-81. doi: 10.1016/0883-2897(91)90063-q.
引用本文的文献
1
Engineering Next-Generation CAR-T Cells for Better Toxicity Management.工程化下一代 CAR-T 细胞以更好地进行毒性管理。
Int J Mol Sci. 2020 Nov 16;21(22):8620. doi: 10.3390/ijms21228620.
2
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.生物制剂（包括生物类似药）的安全性：现状与未来方向的视角。
Drug Saf. 2018 Nov;41(11):1013-1022. doi: 10.1007/s40264-018-0684-9.
3
Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.意大利南部地区癌症治疗中生物和非生物靶向治疗的使用情况及费用：5 年数据。
Clin Drug Investig. 2018 Mar;38(3):269-278. doi: 10.1007/s40261-017-0591-3.
本文引用的文献
1
Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy.使用放射性标记的抗癌胚抗原单克隆抗体通过体外光扫描和断层闪烁扫描检测人类癌症。
Immunol Today. 1981 Dec;2(12):239-49. doi: 10.1016/0167-5699(81)90011-6.
2
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.在胰腺癌中，西妥昔单抗/曲妥珠单抗的双重 EGFR/HER2 靶向治疗比曲妥珠单抗/厄洛替尼或拉帕替尼单药治疗更有效：受体下调和二聚体破坏的影响。
Neoplasia. 2012 Feb;14(2):121-30. doi: 10.1593/neo.111602.
3
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.血管正常化作为治疗恶性和非恶性疾病的一种策略。
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006486. doi: 10.1101/cshperspect.a006486.
4
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.用 CD137 特异性抗体刺激自然杀伤细胞可增强曲妥珠单抗在乳腺癌异种移植模型中的疗效。
J Clin Invest. 2012 Mar;122(3):1066-75. doi: 10.1172/JCI61226. Epub 2012 Feb 13.
5
An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab.一种去岩藻糖基化抗 CD20 单克隆抗体，与利妥昔单抗相比，具有更强的抗体依赖性细胞细胞毒性和 B 细胞耗竭作用，以及更低的补体依赖性细胞毒性。
Mol Immunol. 2012 Mar;50(3):134-41. doi: 10.1016/j.molimm.2012.01.001. Epub 2012 Feb 2.
6
Immunocytokines: a novel class of potent armed antibodies.免疫细胞因子：一类新型强效武装抗体。
Drug Discov Today. 2012 Jun;17(11-12):583-90. doi: 10.1016/j.drudis.2012.01.007. Epub 2012 Jan 24.
7
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.抗血管内皮生长因子治疗后肿瘤内化疗药物输送迅速减少：对抗血管生成药物治疗方案的影响。
Cancer Cell. 2012 Jan 17;21(1):82-91. doi: 10.1016/j.ccr.2011.11.023.
8
Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma.放射性免疫治疗巩固和利妥昔单抗维持治疗在滤泡性淋巴瘤的初始治疗中。
EJNMMI Res. 2011 Jun 20;1(1):7. doi: 10.1186/2191-219X-1-7.
9
Cancer immunotherapy comes of age.癌症免疫疗法崭露头角。
Nature. 2011 Dec 21;480(7378):480-9. doi: 10.1038/nature10673.
10
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。
Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
Zotero 插件